New trial examines the effectiveness of a two-pronged immunotherapy for glioblastomas

A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.